Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150091 | 0.83 | MYC (0.36) | LMNASMN1; SMN2CTSB | |
| SCHEMBL9368951 | 0.80 | ALDH1A1 (0.41) | ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL10593353 | 0.80 | KCNH2 (0.38) | DRD2TP53 | |
| SCHEMBL3057169 | 0.78 | HSD11B1 (0.33) | DRD2LOXBCAT2 | |
| SCHEMBL3712440 | 0.74 | — | — | |
| SCHEMBL3835232 | 0.74 | L3MBTL1 (0.35) | DRD2ALDH1A1LOXBCAT2 | |
| SCHEMBL6976387 | 0.74 | BCAT2 (0.33) | DRD2LOXBCAT2 | |
| SCHEMBL64051 | 0.73 | GABRA1 (0.41) | — | |
| SCHEMBL11567026 | 0.72 | CA1 (0.34) | LOXBCAT2 | |
| SCHEMBL2653491 | 0.72 | ACLY (0.33) | LOXBCAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0715618-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-06-12 | — | — | EP | claimed |
| EP-3303337-B1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-05-27 | — | — | EP | disclosed |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2019-11-12 | — | — | US | disclosed |
| EP-3080114-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-10-02 | — | — | EP | disclosed |
| EP-3080113-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-18 | — | — | EP | disclosed |
| EP-3080121-B1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-20180298006-A1 | Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity | UCB S.A. (BE) | 2018-10-18 | — | — | US | disclosed |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | disclosed |
| EP-3303337-A1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| US-9932343-B2 | Fused tricyclic benzimidazoles derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | disclosed |
| US-20160376268-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-12-29 | — | — | US | disclosed |
| WO-2016198398-A1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2016-12-15 | — | — | WO | disclosed |
| US-20160304530-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | UCB PHARMA S.A. (BE) | 2016-10-20 | — | — | US | disclosed |
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-10-20 | — | — | US | disclosed |
| EP-3080121-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080113-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080114-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086527-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086526-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086525-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298006-A1 | Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | DRD2 3493/4885ALDH1A1 1598/4885LMNA 3433/4885 |
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | DRD2 2173/4885ALDH1A1 205/4885LMNA 3253/4885 |
| US-20160376268-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | DRD2 1554/4885ALDH1A1 1999/4885LMNA 4038/4885 |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | DRD2 1554/4885ALDH1A1 1999/4885LMNA 4038/4885 |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | TNF, TNFRSF1A, TNFRSF9 | DRD2 3460/4885ALDH1A1 1283/4885LMNA 3187/4885 |
| US-20160304530-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | DRD2 731/4885ALDH1A1 1080/4885LMNA 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.